PARP1 and cancer: Olaparib is a selective inhibitor of the poly (ADP-ribose) polymerase (PARP) enzymes (PARP1 and PARP2), which works by taking advantage of the defect in DNA repair in cancer cells with BRCA mutations and inducing cell death [33].